SMTI (SMTI) revenue breakdown
By product, Soft Tissue Repair Products is the largest at 89% of fiscal 2025 revenue; Bone Fusion Products grew fastest, 43% a year over 3 years.
Revenue by product
Fiscal years, as SMTI reports them in its 10-K filings; fiscal 2025 total $103M.
| Products | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| Soft Tissue Repair Products | — | — | — | $42M | $55M | $76M | $91M | 89% |
| Bone Fusion Products | — | — | — | $4M | $10M | $11M | $12M | 11% |
| Sanara Legacy Product Sales | $12M | $15M | $24M | — | — | — | — | — |
| Royalty | $159,125 | $201,000 | $201,000 | $201,000 | $201,000 | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for SMTI.
Open SMTI in InvestinglyQuestions
Where does SMTI make its money?
In fiscal 2025, by product: Soft Tissue Repair Products $91M, Bone Fusion Products $12M.
From SMTI's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.